Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING

Core Points - Hofseth BioCare ASA (HBC) is conducting a private placement of new shares, with the completion of tranche 2 (T2 Offer Shares) contingent upon an extraordinary general meeting (EGM) [1] - The EGM is scheduled for 20 November 2025, and the company has secured voting commitments from shareholders to meet the majority requirement for approval [2] Company Overview - HBC is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources, converting by-products from the salmon industry into health-improving ingredients [3] - The company offers products such as ProGo®, OmeGo®, and CalGo® / NT-II®, which are designed to enhance human and pet health [4] Scientific and Health Benefits - HBC emphasizes scientific evidence in its product development, leading to partnerships and the identification of health benefits, including improved iron metabolism and immune health [5] - The company has secured several patents for its discoveries and has established a biotech subsidiary, AecorBio Inc., focusing on therapeutics for prostate and ovarian cancer, as well as asthma [6] Market Presence - HBC is listed on the Oslo Stock Exchange under the ticker "HBC" [7]